Neuroscience
From MedPage Today:
FDA Puts Early Alzheimer's Test on Hold
By Peggy Peck, Executive Editor
MedPage Today
Published: March 18, 2011
[snip]
"The FDA will not approve the novel contrast agent, florbetapir -- widely touted as a breakthrough for early diagnosis of Alzheimer's disease -- until manufacturer Eli Lilly puts a training program in place, the company announced."
[snip]
Read the article.
- Alzheimer's Disease: Genomic Data
Press release from the NIH: NIH deposits first batch of genomic data for Alzheimer’s disease Researchers gain rapid access to first set of raw human genome sequence 02 December 2013 [snip] "Researchers can now freely access the first batch of genome...
- Clinical Trials: Solanezumab In Alzheimer's Disease
From Bloomberg: Eli Lilly Shares Rise on Alzheimer’s Drug Hopes By Drew Armstrong and Robert Langreth Dec 6, 2011 [snip] "Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s...
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
From The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By THE ASSOCIATED PRESS Published: January 20, 2011 Filed at 5:40 p.m. ESTWASHINGTON (AP) — A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical...
- World Alzheimer's Day
Today is World Alzheimer's Day. Read something today to increase your knowledge about the disease and dementia. Here's a general-readership resource: Alzheimer's Disease: Unraveling the Mystery ... and a report from the Alzheimer's Association:...
- Imaging Alzheimer Disease - Part 2
Today's Yale Daily News includes an article about last week's announcement about the initiative to examine imaging technologies in the diagnosis of Alzheimer disease. The article is interesting to read of itself, but also because it touches briefly...
Neuroscience
FDA: Alzheimer's, Amyvid (florbetapir)
From MedPage Today:
FDA Puts Early Alzheimer's Test on Hold
By Peggy Peck, Executive Editor
MedPage Today
Published: March 18, 2011
[snip]
"The FDA will not approve the novel contrast agent, florbetapir -- widely touted as a breakthrough for early diagnosis of Alzheimer's disease -- until manufacturer Eli Lilly puts a training program in place, the company announced."
[snip]
Read the article.
- Alzheimer's Disease: Genomic Data
Press release from the NIH: NIH deposits first batch of genomic data for Alzheimer’s disease Researchers gain rapid access to first set of raw human genome sequence 02 December 2013 [snip] "Researchers can now freely access the first batch of genome...
- Clinical Trials: Solanezumab In Alzheimer's Disease
From Bloomberg: Eli Lilly Shares Rise on Alzheimer’s Drug Hopes By Drew Armstrong and Robert Langreth Dec 6, 2011 [snip] "Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s...
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
From The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By THE ASSOCIATED PRESS Published: January 20, 2011 Filed at 5:40 p.m. ESTWASHINGTON (AP) — A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical...
- World Alzheimer's Day
Today is World Alzheimer's Day. Read something today to increase your knowledge about the disease and dementia. Here's a general-readership resource: Alzheimer's Disease: Unraveling the Mystery ... and a report from the Alzheimer's Association:...
- Imaging Alzheimer Disease - Part 2
Today's Yale Daily News includes an article about last week's announcement about the initiative to examine imaging technologies in the diagnosis of Alzheimer disease. The article is interesting to read of itself, but also because it touches briefly...